Microbot Medical has commenced the full market release (FMR) of its LIBERTY® Endovascular Robotic System in the U.S., following the successful completion of its limited market release across multiple leading healthcare systems. The milestone was formally unveiled at the Society of Interventional Radiology (SIR) Annual Scientific Meeting 2026 in Toronto, the company’s first major commercial showcase at the event. 

The company said the limited rollout has already resulted in adoption across multiple health systems spanning dozens of hospitals, including major academic networks such as Emory Healthcare and Tampa General Hospital, providing strong early validation ahead of nationwide expansion. 

LIBERTY is positioned as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, creating a new category in interventional robotics. The platform has already been used commercially across a wide range of procedures, including prostate artery embolization (PAE), uterine fibroid embolization (UFE), genicular artery embolization (GAE), Y90 mapping and delivery, and peripheral arterial interventions. 

Physician feedback from the limited release has highlighted the system’s precision, rapid setup, short learning curve, compatibility with preferred wires and catheters, and workflow efficiency gains, including reduced procedure times and fewer instruments required per case.

“We successfully achieved our goals for the limited market release of the LIBERTY System, including its adoption by leading hospitals across multiple peripheral procedures, giving us the momentum to commence, as planned, the full market release at the SIR conference,” said Harel Gadot, Chairman, President & CEO, Microbot Medical. 

The company is also scaling its commercial infrastructure in parallel with the launch, doubling its U.S. sales footprint from four to eight territories, with plans to reach 12 territories by the end of 2026. This expanded field presence is expected to accelerate penetration into both existing and new hospital networks.